Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress

Stock Information for Palisade Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Palisade Bio Inc.

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis(TM)
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Palisade Bio Provides Corporate Update and Reiterates Guidance
Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.